✨
AI Summary
- Supreme Court upholds generic 'skinny labels,' impacting industry adaptation.
- FDA's National Priority Program faces an uncertain future.
- Discussion on how the generic industry will navigate new regulatory landscapes.
Guests on This Episode
DW
David Wallace
3 podcast appearances
DG
Derrick Gingery
8 podcast appearances
MO
Maaisha Osman
4 podcast appearances
NH
Nielsen Hobbs
8 podcast appearances
SS
Sue Sutter
8 podcast appearances